Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Recurrent noncoding regulatory mutations in pancreatic ductal adenocarcinoma.

Feigin ME, Garvin T, Bailey P, Waddell N, Chang DK, Kelley DR, Shuai S, Gallinger S, McPherson JD, Grimmond SM, Khurana E, Stein LD, Biankin AV, Schatz MC, Tuveson DA.

Nat Genet. 2017 Jun;49(6):825-833. doi: 10.1038/ng.3861. Epub 2017 May 8.

2.

Mutations in Mitochondrial DNA From Pancreatic Ductal Adenocarcinomas Associate With Survival Times of Patients and Accumulate as Tumors Progress.

Hopkins JF, Denroche RE, Aguiar JA, Notta F, Connor AA, Wilson JM, Stein LD, Gallinger S, Boutros PC.

Gastroenterology. 2018 May;154(6):1620-1624.e5. doi: 10.1053/j.gastro.2018.01.029. Epub 2018 Mar 29.

PMID:
29378198
3.

GNAS mutation is a frequent event in pancreatic intraductal papillary mucinous neoplasms and associated adenocarcinomas.

Hosoda W, Sasaki E, Murakami Y, Yamao K, Shimizu Y, Yatabe Y.

Virchows Arch. 2015 Jun;466(6):665-74. doi: 10.1007/s00428-015-1751-6. Epub 2015 Mar 22.

PMID:
25796395
4.

Long non-coding RNAs expressed in pancreatic ductal adenocarcinoma and lncRNA BC008363 an independent prognostic factor in PDAC.

Li J, Liu D, Hua R, Zhang J, Liu W, Huo Y, Cheng Y, Hong J, Sun Y.

Pancreatology. 2014 Sep-Oct;14(5):385-90. doi: 10.1016/j.pan.2014.07.013. Epub 2014 Aug 12.

PMID:
25200694
5.

Genome-wide DNA methylation patterns in pancreatic ductal adenocarcinoma reveal epigenetic deregulation of SLIT-ROBO, ITGA2 and MET signaling.

Nones K, Waddell N, Song S, Patch AM, Miller D, Johns A, Wu J, Kassahn KS, Wood D, Bailey P, Fink L, Manning S, Christ AN, Nourse C, Kazakoff S, Taylor D, Leonard C, Chang DK, Jones MD, Thomas M, Watson C, Pinese M, Cowley M, Rooman I, Pajic M; APGI, Butturini G, Malpaga A, Corbo V, Crippa S, Falconi M, Zamboni G, Castelli P, Lawlor RT, Gill AJ, Scarpa A, Pearson JV, Biankin AV, Grimmond SM.

Int J Cancer. 2014 Sep 1;135(5):1110-8. doi: 10.1002/ijc.28765. Epub 2014 May 9.

6.

Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes.

Biankin AV, Waddell N, Kassahn KS, Gingras MC, Muthuswamy LB, Johns AL, Miller DK, Wilson PJ, Patch AM, Wu J, Chang DK, Cowley MJ, Gardiner BB, Song S, Harliwong I, Idrisoglu S, Nourse C, Nourbakhsh E, Manning S, Wani S, Gongora M, Pajic M, Scarlett CJ, Gill AJ, Pinho AV, Rooman I, Anderson M, Holmes O, Leonard C, Taylor D, Wood S, Xu Q, Nones K, Fink JL, Christ A, Bruxner T, Cloonan N, Kolle G, Newell F, Pinese M, Mead RS, Humphris JL, Kaplan W, Jones MD, Colvin EK, Nagrial AM, Humphrey ES, Chou A, Chin VT, Chantrill LA, Mawson A, Samra JS, Kench JG, Lovell JA, Daly RJ, Merrett ND, Toon C, Epari K, Nguyen NQ, Barbour A, Zeps N; Australian Pancreatic Cancer Genome Initiative, Kakkar N, Zhao F, Wu YQ, Wang M, Muzny DM, Fisher WE, Brunicardi FC, Hodges SE, Reid JG, Drummond J, Chang K, Han Y, Lewis LR, Dinh H, Buhay CJ, Beck T, Timms L, Sam M, Begley K, Brown A, Pai D, Panchal A, Buchner N, De Borja R, Denroche RE, Yung CK, Serra S, Onetto N, Mukhopadhyay D, Tsao MS, Shaw PA, Petersen GM, Gallinger S, Hruban RH, Maitra A, Iacobuzio-Donahue CA, Schulick RD, Wolfgang CL, Morgan RA, Lawlor RT, Capelli P, Corbo V, Scardoni M, Tortora G, Tempero MA, Mann KM, Jenkins NA, Perez-Mancera PA, Adams DJ, Largaespada DA, Wessels LF, Rust AG, Stein LD, Tuveson DA, Copeland NG, Musgrove EA, Scarpa A, Eshleman JR, Hudson TJ, Sutherland RL, Wheeler DA, Pearson JV, McPherson JD, Gibbs RA, Grimmond SM.

Nature. 2012 Nov 15;491(7424):399-405. doi: 10.1038/nature11547. Epub 2012 Oct 24.

7.

Relevance of Sp Binding Site Polymorphism in WWOX for Treatment Outcome in Pancreatic Cancer.

Schirmer MA, Lüske CM, Roppel S, Schaudinn A, Zimmer C, Pflüger R, Haubrock M, Rapp J, Güngör C, Bockhorn M, Hackert T, Hank T, Strobel O, Werner J, Izbicki JR, Johnsen SA, Gaedcke J, Brockmöller J, Ghadimi BM.

J Natl Cancer Inst. 2016 Feb 8;108(5). doi: 10.1093/jnci/djv387. Print 2016 May.

8.

Association of microRNA-21 expression with its targets, PDCD4 and TIMP3, in pancreatic ductal adenocarcinoma.

Nagao Y, Hisaoka M, Matsuyama A, Kanemitsu S, Hamada T, Fukuyama T, Nakano R, Uchiyama A, Kawamoto M, Yamaguchi K, Hashimoto H.

Mod Pathol. 2012 Jan;25(1):112-21. doi: 10.1038/modpathol.2011.142. Epub 2011 Oct 7.

9.

Exome sequencing and digital PCR analyses reveal novel mutated genes related to the metastasis of pancreatic ductal adenocarcinoma.

Zhou B, Irwanto A, Guo YM, Bei JX, Wu Q, Chen G, Zhang TP, Lei JJ, Feng QS, Chen LZ, Liu J, Zhao YP.

Cancer Biol Ther. 2012 Aug;13(10):871-9. doi: 10.4161/cbt.20839. Epub 2012 Aug 1.

PMID:
22797009
10.

Genomic Testing for Gemcitabine-Based Treatment of Pancreatic Cancer.

Zhang J, Hochwald SN.

J Natl Cancer Inst. 2016 Feb 8;108(5). pii: djv424. doi: 10.1093/jnci/djv424. Print 2016 May. No abstract available.

PMID:
26857393
11.

Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine.

Knudsen ES, O'Reilly EM, Brody JR, Witkiewicz AK.

Gastroenterology. 2016 Jan;150(1):48-63. doi: 10.1053/j.gastro.2015.08.056. Epub 2015 Sep 15. Review.

12.

Large duct type invasive adenocarcinoma of the pancreas with microcystic and papillary patterns: a potential microscopic mimic of non-invasive ductal neoplasia.

Bagci P, Andea AA, Basturk O, Jang KT, Erbarut I, Adsay V.

Mod Pathol. 2012 Mar;25(3):439-48. doi: 10.1038/modpathol.2011.181. Epub 2011 Nov 4.

13.

[Topoisomerase IIalpha and HER2/neu gene alterations and their correlation in pancreatic ductal adenocarcinomas].

Liang ZY, Wang WZ, Gao J, Wu SF, Zeng X, Liu TH.

Zhonghua Bing Li Xue Za Zhi. 2007 Feb;36(2):102-6. Chinese.

PMID:
17493384
14.

Expression of long non-coding RNA LOC285194 and its prognostic significance in human pancreatic ductal adenocarcinoma.

Ding YC, Yu W, Ma C, Wang Q, Huang CS, Huang T.

Int J Clin Exp Pathol. 2014 Oct 15;7(11):8065-70. eCollection 2014.

15.

Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.

Ruggeri BA, Huang L, Berger D, Chang H, Klein-Szanto AJ, Goodrow T, Wood M, Obara T, Heath CW, Lynch H.

Cancer. 1997 Feb 15;79(4):700-16.

PMID:
9024708
16.

A GNAS mutation found in pancreatic intraductal papillary mucinous neoplasms induces drastic alterations of gene expression profiles with upregulation of mucin genes.

Komatsu H, Tanji E, Sakata N, Aoki T, Motoi F, Naitoh T, Katayose Y, Egawa S, Unno M, Furukawa T.

PLoS One. 2014 Feb 3;9(2):e87875. doi: 10.1371/journal.pone.0087875. eCollection 2014.

17.

Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.

Wang WQ, Liu L, Xu HX, Wu CT, Xiang JF, Xu J, Liu C, Long J, Ni QX, Yu XJ.

Br J Surg. 2016 Aug;103(9):1189-99. doi: 10.1002/bjs.10187. Epub 2016 Jun 3.

PMID:
27256393
18.

Prognostic significance of microRNA-141 expression and its tumor suppressor function in human pancreatic ductal adenocarcinoma.

Zhu ZM, Xu YF, Su QJ, Du JD, Tan XL, Tu YL, Tan JW, Jiao HB.

Mol Cell Biochem. 2014 Mar;388(1-2):39-49. doi: 10.1007/s11010-013-1897-y. Epub 2013 Nov 17.

PMID:
24242138
19.

Upregulation of integrin β4 promotes epithelial-mesenchymal transition and is a novel prognostic marker in pancreatic ductal adenocarcinoma.

Masugi Y, Yamazaki K, Emoto K, Effendi K, Tsujikawa H, Kitago M, Itano O, Kitagawa Y, Sakamoto M.

Lab Invest. 2015 Mar;95(3):308-19. doi: 10.1038/labinvest.2014.166. Epub 2015 Jan 19.

20.

Prognostic relevance of molecular subtypes and master regulators in pancreatic ductal adenocarcinoma.

Janky R, Binda MM, Allemeersch J, Van den Broeck A, Govaere O, Swinnen JV, Roskams T, Aerts S, Topal B.

BMC Cancer. 2016 Aug 12;16:632. doi: 10.1186/s12885-016-2540-6.

Supplemental Content

Support Center